Sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin may stimulate erythropoiesis and improve functional iron deficiency in patients with type 2 diabetes and heart failure [88]. This evidence concerns the gene SLC5A2 and Iron deficiency anemia.